Dave Fornell is the editor of DAIC magazine at TCT.
Dave Fornell, DAIC Editor at TCT
Blog | Dave Fornell, DAIC Editor at TCT | Cath Lab| October 16, 2018

The Innovation Cycle for New Cardiovascular Technology

The cardiovascular innovation cycle presented by TCT Course Director Martin Leon, M.D. at TCT 2018. #TCT2018 #TCT #TCT18

The cardiovascular innovation cycle, presented by TCT Course Director Martin Leon, M.D., at TCT 2018.

There is a hype cycle surrounding new technologies in all industries, but medicine is unique because of its focus on clinical trial data as one of the key determining factors of whether a new device becomes standard of care or dies on the vine. Here is a great summary of this cycle with cardiovascular devices.

Over the past decade of covering the Transcatheter Cardiovascular Therapeutics (TCT) meetings, I have seen an interesting slide on the innovation cycle for interventional cardiology device technologies presented numerous times by Course Director Martin B. Leon, M.D., director of the Center for Interventional Vascular Therapy and professor of medicine, NewYork-Presbyterian, Columbia University Medical Center. The slide is always the same since he first presented it at TCT in 1993, but it holds universally true today in 2018. 

Leon said the cycle starts with the introduction of a new technology that garners unbridled enthusiasm because of the promise the technology holds to solve problems with the current standard of care. The early data seems great and when it enters the market, there is rapid adoption as everyone wants to try to use it. However, there are inevitably some complications that are discovered once the technology is used on a large scale, either due to implant, operator skill or previously unknown complications. When data on the complications are presented, there is a steep drop-off in the use of the technology. 

At this point in the cycle, Leon said it is important to refine the technology to overcome the issues presented by the first-generation device. Once that is achieved and clinical data confirms the issues are resolved, there is a second wave of adoption for the technology, as cardiologists are cautiously optimistic about using the improved technology. He said that crash where the enthusiasm dissolves because of cold, hard data is when the real science of refining the technology into something better can take place. 

Certainly this cycle mirrored the case with drug-eluting stents and the discovery of polymer-related late-stent thrombosis. The same is true with renal denervation and bioresorbable stents.

At TCT 2018, Leon used this slide in sessions to describe where interventional cardiology is at today with bioresorbable stent technology — at the bottom of the abyss. However, he said there are new bioresorbable technologies still being developed that already hold promise to resolve the issues inherent with the first-generation Absorb stent. This includes new bioresorbable scaffolds (BRS) that use different polymers to possibly avoid late thrombosis, and devices with the same strut thickness of today's metallic stents to make the devices easier to deliver and allow use in smaller vessels. 

Two years ago, all TCT sessions on bioresorbable technologies were packed and it seemed as if metallic stents had no long-term future. What a difference a year makes from TCT 2017, when the poor ABSORB III Trial data was presented and Abbott pulled the Absorb off the market. At TCT 2018, bioresorbable technology definitely took a back seat to metallic stent presentations, where the industry has definitely refocused its interest. 

"I want to be a wild enthusiast, not a doubting skeptic," Leon said about BRS technology. "The Absorb was not easy to use and there was a safety concern. The safety signal is really what distracted people's attention with bioresorbable stents. We are not going to have an avalanche of new bioresorbable stents, but there will be a few second-generation stents that have overcome the limitations of the first-generation stent."

However, the new clinical evidence will have to be persuasive enough with these new BRS devices to convince him and the rest of the interventional cardiology community that the technology is truly ready for prime time.

Read the article from TCT 2018 "The Next Step in Bioresorbable Stent Technologies."

Watch an interview with Patrick Serruys, M.D., about the future of BVS technology.

Related Content

Medical Bills Financially Burden Almost Half of Cardiovascular Disease Patients
News | Cardiovascular Business | February 11, 2019
Over 45 percent of adult atherosclerotic cardiovascular disease (ASCVD) patients suffer financial hardship related to...
Researchers raised the question whether an economic benefit should be assessed in FDA reviews. A large amount of the bill for atrial fibrillation catheter ablation procedures is the cost of the mapping and ablation catheters.

A large amount of the bill for atrial fibrillation catheter ablation procedures is the cost of the mapping and ablation catheters. Researchers raised the question whether an economic benefit should be assessed in FDA reviews. 

Feature | Cardiovascular Business | January 14, 2019 | Philip Jacobs, DPhil, Ilke Akpinar, M.D., Thanh Nguyen, M.D., Ph.D., Rupinder Sandhu, M.D., and Lars Thording Ph.D.
In an age when everything in medicine is now looked at though a cost vs. benefit analysis and U.S.
GE Submits Initial Public Offering Paperwork for Healthcare Division
News | Cardiovascular Business | December 19, 2018
As part of its plans to spin off its healthcare division into a separate company, GE reportedly submitted the paperwork...
Affordable Care Act Ruled Unconstitutional in Texas Federal Court
News | Cardiovascular Business | December 17, 2018
A judge of the Federal District Court for the Northern District of Texas ruled the Affordable Care Act (ACA)...
Average Age of U.S. Cardiologists Up While Income is Down
News | Cardiovascular Business | October 25, 2018
Overall cardiology compensation has dropped for the first time since 2014, according to the sixth annual Cardiovascular...
American Heart Association and The Joint Commission Merge Cardiac Certification Programs
News | Cardiovascular Business | October 15, 2018
The nation’s two leading cardiac accreditation and certification organizations are joining forces to offer a single...
A hands-on-training session at TCT 2018 that instructed interventional cardiologists how to use an intra-cardiac echo (ICE) catheter to image the chambers inside the heart with a catheter based ultrasound imaging system.  The training area was sponsored by Siemens Healthineers

A Siemens-sponsored hands-on-training session at TCT 2018 that instructed interventional cardiologists how to use an intra-cardiac echo (ICE) catheter to image the chambers inside the heart with a catheter based ultrasound imaging system.  Regular training is needed to build customer satisfaction, especially in light of regular staff turnover.

Feature | Cardiovascular Business | October 10, 2018 | John Larson
Years ago, I owned a computer that ran a spreadsheet program called Lotus 1-2-3.
ZHealth Launches Etch Cardiovascular Coding Software
Technology | Cardiovascular Business | October 10, 2018
October 10, 2018 — Medical coding software provider ZHealth recently unveiled Etch, the first-ever software platform
GlobalData: Amazon Poised to Make Huge Strides in Healthcare
News | Cardiovascular Business | August 31, 2018
A new report from data and analytics company GlobalData suggests that Amazon is poised to make huge strides in...
CMS Proposes Overhaul of Medicare's Accountable Care Organization Program
News | Cardiovascular Business | August 09, 2018
The Centers for Medicare & Medicaid Services (CMS) issued a proposed rule August 9 that would overhaul the Medicare...
Overlay Init